Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study

被引:0
作者
Milan Gupta
Rajvi J. Wani
Khalid Al Faraidy
Jean Bergeron
Eduardo Contreras
Angel Alberto Garcia Peña
G. B. John Mancini
Francisco Padilla
Abel Alberto Pavia Lopez
Kiran Philip
Johnny Wu
Erin S. Mackinnon
机构
[1] University of Toronto and the Canadian Collaborative Research Network,Department of Medicine
[2] Amgen Canada Inc.,ICT Department
[3] Interventional Cardiology,Departments of Medicine and of Laboratory Medicine
[4] King Fahad Military Medical City,Division of Cardiology
[5] Centre Hospitalier Universitaire de Québec-Université Laval,Centre for Cardiovascular Innovation, Division of Cardiology, Department of Medicine
[6] Clinica de Occidente – Angiografia de Occidente,Clinical and Interventional Cardiology
[7] Hospital Universitario San Ignacio,undefined
[8] Pontificia Universidad Javeriana,undefined
[9] University of British Columbia,undefined
[10] Clinical and Interventional Research,undefined
[11] Cardiovascular Center Chapalita,undefined
[12] Centro Medico ABC,undefined
[13] Amgen Inc.,undefined
来源
Cardiology and Therapy | 2023年 / 12卷
关键词
Atherosclerotic cardiovascular disease (ASCVD); Evolocumab; Familial hypercholesterolemia (FH); Low-density lipoprotein cholesterol (LDL-C); Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:703 / 722
页数:19
相关论文
共 99 条
[1]  
Silverman MG(2016)Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis JAMA 316 1289-1297
[2]  
Ference BA(2017)Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel Eur Heart J 38 2459-2472
[3]  
Im K(2019)2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines J Am Coll Cardiol 73 e285-e350
[4]  
Ference BA(2020)2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk Eur Heart J 41 111-188
[5]  
Ginsberg HN(2021)2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult Can J Cardiol 37 1129-1150
[6]  
Graham I(2014)2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 129 S1-45
[7]  
Grundy SM(2019)Assessing low-density lipoprotein cholesterol risk in secondary prevention patients within the PINNACLE National Outpatient Registry Circulation 140 A12904-166
[8]  
Stone NJ(2017)Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II Atherosclerosis 266 158-9
[9]  
Bailey AL(2014)Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment PLoS One 9 1-460
[10]  
Mach F(2021)Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US JAMA Cardiol 6 447-517